Abstract. The impact of hepatitis C virus-positive donor kidneys on patient survival has not been analyzed in a national study. This study analyzed 20,111 adult (age, Ն16 yr) recipients having solitary cadaveric kidney transplants from adult donors with valid donor hepatitis C serologies from
Among hepatitis C-positive recipients, those who received hepatitis C-positive kidneys had worse survival than recipients of hepatitis C-negative kidneys. Among elderly hepatitis C-negative recipients, those who received hepatitis C-positive kidneys also had worse survival; in fact, all recipients of donor hepatitis C-positive kidneys had increased risk of mortality (P ϭ 0.028). There were no significant interactions between donor hepatitis C positivity and either recipient hepatitis C positivity or older recipient age. The use of hepatitis C-positive kidneys in recipients who were hepatitis C-negative was fairly common and contrary to some current recommendations. Recipients of donor hepatitis C-positive kidneys were at independently increased risk of mortality, with no evidence that any subgroups were less affected.
Infection with hepatitis C virus (HCV) is a major cause of morbidity and mortality in the United States kidney transplant population and in patients with end-stage renal disease (ESRD) (1, 2) . Testing for HCV is required in all cases of cadaveric organ donation, but no firm consensus prevails regarding the allocation of hepatitis C-positive organs (3) . Of particular concern is the high prevalence of HCV among kidney donors: nationwide, 4.2% of cadaveric organ donors demonstrated antibodies to HCV (4 -6) compared with 1.8% in the general population (7) .
Although many studies show that HCV acquired before kidney transplantation results in increased morbidity and mortality (8 -12) , the impact of HCV acquired at the time of transplantation is less well defined (13) . It is, however, generally accepted that a recipient who was HCV-negative before organ transplantation may acquire HCV from an HCV-positive donor organ (14) , a circumstance associated with increased incidence of posttransplant liver disease (14 -19) . As yet, no difference in post-kidney transplant patient or graft survival regarding either donor or recipient hepatitis C status has been demonstrated. Absent definitive data, opinions regarding the proper use of hepatitis C-positive kidneys have varied widely (4,13,16,20 -25) .
Better characterization of the clinical course of patients receiving hepatitis C-positive kidneys is essential to developing a rational allocation strategy that maximizes safe usage and minimizes discard of otherwise suitable donor organs. To determine if donor hepatitis C serology had any significant relationship with graft and patient survival adjusted for other factors, we conducted an historical cohort study analyzing the 2000 United States Renal Data System (USRDS) data to assess factors associated with hepatitis C-positive kidneys, controlling for variables previously established to affect graft and patient survival.
Materials and Methods

Data Sources and Study Sample
The present analysis used a data set and analytical techniques that have been previously described (26) . In summary, the USRDS standard analysis file (SAF) SAF.TXUNOS was the primary file including baseline information. Information on medications was limited to immunosuppressive medications. This file was merged with SAF. TXFUUNOS by using unique patient identifying codes to obtain follow-up data. The file was also merged with SAF.PATIENTS to obtain dates and causes of death. Donor HCV serology was not collected by UNOS before April 1, 1994 (27) . In addition, less than 0.5% of living donor kidneys were seropositive for HCV. Therefore, analysis was limited to adult patients who underwent cadaveric kidney transplantation from July 1, 1994, to June 30, 1998 . Only the first transplant for a given patient during the study period (which could have been a repeat transplant) was included in analysis. Cases with unknown recipient HCV status were not excluded from univariate analysis to allow complete analysis of associations of other factors related to donor HCV status. However, in outcome comparisons relating recipient and donor HCV status, only cases with specified HCV data for both donor and recipient were included. HCV serology was not independently confirmed. Similarly, the cause of ESRD was also not independently confirmed. Patients were followed through April 2000.
Analytic Variables and Outcome Measures
Associations with Donor Hepatitis C Status. Singular donor and recipient factors used are listed in Tables 1 and 2 and were entered into multivariable with stepwise Logistic Regression analysis for strength of association with donor hepatitis C status (1 if positive, 0 if negative) if P Ͻ 0.10 in univariate analysis ( 2 for categorical variables; t test for continuous variables). Because hepatitis C-negative recipients transplanted with hepatitis C-positive kidneys might represent a different population, separate logistic regression analysis was performed with all hepatitis C-negative recipients who received hepatitis C-positive kidneys as 1, and all other transplant recipients with valid hepatitis C serologies as 0.
Patient and Graft Survival. Survival time was defined as the time between the date of transplant and death, the most recent follow-up date, or the end of the study period. Logistic regression analysis was used to model associations with donor hepatitis C status, using techniques and variables similar to Cox regression mentioned above. Graft failure was defined as return to dialysis after transplant and did not include death with a functioning graft. Variables entered into the model were those previously associated with patient and graft survival after transplantation (26, 28) . Graft loss was analyzed as a time-dependent variable using previously described methods (29) , because it has recently been recognized as an independent predictor of patient mortality in kidney transplant recipients (30) . Stratified Cox models were performed for each of the following subgroups of particular clinical interest: recipients who were hepatitis C-negative, recipients who were hepatitis C-positive, and recipients who were aged 65 yr or older. Covariates whose Kaplan Meier plots violated the assumption of proportional hazards over time were assessed using yearly intervals after transplantation, as described by previous investigators (31) .
Comorbidity data from Center for Medicare and Medicaid Studies (CMS) Form 2728 was only available for a minority of recipients. Therefore, hospitalizations for cardiovascular disease (32) and for liver disease (8, 33, 34) , because of their possible relationship with later all-cause or liver-related morbidity and mortality in ESRD patients, were extracted from the USRDS database (any appearance of these diagnoses in the final five discharge diagnoses), merged with the patient files, and used as covariates in subsequent analyses.
Results
There were 24,262 adult recipients of solitary cadaveric kidney transplants meeting study criteria in the United States from July 1, 1994, to June 30, 1998 . Of these, 3953 were missing follow-up data, leaving 20,309 recipients for whom data could be assessed by univariate analysis. Only 198 (1%) of recipients had no data regarding their donor hepatitis C status; they and an additional 2414 (12%) lacking data for recipient HCV status were excluded, leaving 17,697 patients for study in multivariable analysis. Notably, the 13% of recipients with missing HCV data (their own or their donor) did not differ statistically from patients for whom these data were known. Mean follow-up was 1.85 Ϯ 1.12 yr.
Associations with Donor Hepatitis C Seropositivity
The allocation of kidneys by donor and recipient hepatitis C serology is detailed in Table 1 . As shown, 165 (34%) of donor kidneys positive for hepatitis C were given to recipients who were negative for hepatitis C. The proportion of kidneys from hepatitis C-positive donors transplanted into hepatitis C-positive recipients was stable over the years of the study ( Figure 1) .
A comparison of continuous variables between recipients of donor-positive versus donor-negative kidneys is detailed in Table 2 . In parallel with single-center experience showing reduced time on the transplant waiting list for HCV-positive transplant recipients who received HCV-positive donor kidneys (35) , the duration of time on dialysis before transplant for recipients who were hepatitis C-positive was significantly shorter if they received a hepatitis C-positive kidney than if they received a hepatitis C-negative kidney. Categorical vari- ables for the study population are shown in Table 3 , with results of univariate analysis and logistic regression for their association with donor hepatitis C-positive kidneys and also with recipients who were negative for hepatitis C who received hepatitis C-positive kidneys. The contrast between the two groups is noteworthy: those recipients who were negative for hepatitis C who received hepatitis C-positive kidneys were more likely to be African American, older, recipients of kidneys from cytomegalovirus-positive donors, as well as being recipients of repeat transplants. Significant associations between immunosuppressive medications and donor hepatitis C-positive status were seen in univariate, but not multivariate, analysis, primarily confounded by African American race. Patients who received hepatitis C-positive kidneys were more likely to receive kidneys from African American donors, were at the extremes of age, and had higher levels of HLA mismatch, longer cold ischemic time, and some element of geographic variation. However, such patients were much less likely to have cardiovascular comorbidity at presentation to ESRD. Chronic lung disease and drug use were more often noted in these recipients, but both conditions were relatively infrequent compared with cardiovascular disease.
Among hepatitis C-negative recipients who were transplanted with hepatitis C-positive kidneys, however, recipient (not donor) African American race and male gender were more common, as were receipt of kidneys positive for cytomegalovirus and repeat transplantation; HLA mismatching and cold ischemic time were similar, whereas geographic variation was less marked, and there was no significant association with comorbidity in comparison with all recipients of hepatitis C-positive kidneys. A stratified model limited only to all patients with valid HCV data who received hepatitis C positive kidneys was also performed. In this analysis, hepatitis C-negative recipients who received hepatitis C-positive kidneys were older, experienced greater HLA mismatching with the donor, and received kidneys with a longer cold ischemic time when these factors were compared in recipients who were hepatitis C-positive.
Patient and Graft Survival
Kaplan-Meier plots are shown comparing survival of recipients transplanted with hepatitis C-positive kidneys versus recipients transplanted with hepatitis C-negative kidneys, stratified for hepatitis C-negative recipients only (Figure 2 ), hepatitis C-positive recipients only (Figure 3) , recipients aged Ն65 yr (Figure 4) , and recipients of hepatitis C-positive kidneys comparing the effect of recipient hepatitis C status ( Figure  5 ). Survival was worse for recipients of hepatitis C-positive kidneys in all subgroups. However, in analysis limited to recipients who were hepatitis C-positive (Figure 3) , differences in survival were not seen until 1 yr after transplant. Because this violated the assumption of proportional hazards over time, separate analysis was performed limited to patients who survived at least 2 yr after transplantation. In this group, differences in survival were statistically significant in both unadjusted analysis and in multivariable analysis (Figure 3) . Among patients who received hepatitis C-positive kidneys, recipients who were hepatitis C-negative had trends toward increased mortality, although this was not statistically significant ( Figure 5) . Donor hepatitis C positivity was independently significant in Cox regression analysis of patient survival (Table 3) . Other factors significantly associated with decreased patient survival Table 2 were entered into stepwise Cox regression analysis (see Materials and Methods section for covariates used). Only variables significant in final analysis are shown. For variables in quartiles, the hazard ratio is for higher quartiles above the mean.
b Time-dependent covariate, reflecting the relative risk of death in the time interval occurring after graft failure. Rejection could not be assessed as a time-dependent covariate because the exact date of rejection was not specified, other than as determined within 1 yr posttransplant. (increased hazard ratio) were consistent with prior studies (26, 28) . Interactions between donor hepatitis C status and recipient hepatitis C status, as well as donor hepatitis C status and recipient age Ն65 yr, were not statistically significant.
In stratified analysis limited to patients who received hepatitis C-positive kidneys, recipient hepatitis C status was not significantly associated with mortality, whether the model included comorbidities from Form 2728 or not. Donor hepatitis C positivity was not independently significant in Cox regression analysis of graft survival (P ϭ 0.37), compared with recipient hepatitis C positivity (P ϭ 0.0048). Causes of graft failure for hepatitis C-positive recipients were not different from hepatitis C-negative recipients.
Causes of death were listed as blank or unknown in more than 45% of cases. Among recipients of donor hepatitis C-positive kidneys, the cause of death was missing or unknown in 44.8% of cases. Overall, cardiovascular causes of death were the most frequent cause of death for recipients of either donor hepatitis C-positive (56%) or donor hepatitis C-negative (49%) kidneys, followed by infection for donor hepatitis C-positive (28%) or donor hepatitis C-negative (32%) recipients. Deaths due to liver disease were more common for recipients of donor hepatitis C-positive kidneys (6.6%) than for recipients of donor hepatitis C-negative kidneys (0.5%). Deaths due to malignancy were not different between donor hepatitis C-positive (2.2%) and donor hepatitis C-negative recipients (4.4%).
Discussion
Transplantation of donor hepatitis C-positive kidneys was independently associated with poorer patient survival. This was true even among subgroups such as the elderly and recipients with pretransplant HCV positivity. Patient survival curves were distinct soon after transplant for hepatitis C-negative recipients who received hepatitis C-positive kidneys ( Figure  2 ), whereas differences in survival took longer to manifest for hepatitis C-positive recipients who received hepatitis C-positive kidneys (Figure 3 ). The additional mortality incurred by donor hepatitis C-positive kidney recipients was not fully accounted for by death from liver disease, graft failure, or educational status. Also, in contrast with current recommendations (3), more than one third of donor hepatitis C-positive kidneys in the United States were given to hepatitis C-negative recipients.
Although many studies have noted an increased incidence of liver disease among recipients of donor hepatitis C-positive kidneys (14 -17) , none have shown an increase in mortality from all causes until the present study. Because of the long duration between inoculation/viral transmission and development of cirrhosis in patients contracting HCV in the general population (36) , it has been suggested that elderly recipients and those with serious comorbidities are less likely than other recipients to be adversely affected by donor hepatitis C-positive kidneys (37) . The present study indicates that these subgroups were similarly affected, although a survival difference appeared later in recipients who were hepatitis C-positive before transplantation. Interestingly, no recipient group was at greater risk of liver-related mortality, a finding that we cannot fully explain.
Of the 484 donor hepatitis C-positive kidneys among patients with valid HCV serologies in this study, 165 (34.1%) were given to hepatitis C-negative recipients. In comparison with all other recipients, these recipients of hepatitis C-positive kidneys were more likely to be African American and male; in separate comparisons against all other recipients and hepatitis C-positive recipients, respectively, these recipients were older, with a higher HLA mismatch, longer cold ischemic time, and repeat transplant status. Many of these factors are widely considered risks for poorer graft or patient survival, so it is possible that high-risk situations may attend use of donor hepatitis C-positive kidneys, particularly in hepatitis C-negative recipients. Despite this, recipient hepatitis C status was not associated with mortality among recipients of hepatitis C-positive kidneys ( Figure 5 ). The present study could not determine whether the poorer survival of HCV-negative patients who . Kaplan-Meier analysis limited to patients with valid hepatitis C serologies who received hepatitis C-positive kidneys, n ϭ 484. As shown, recipients who were hepatitis C-positive had a lower rate of mortality then hepatitis C-negative recipients over the study period, although this was not significant by log rank test (P ϭ 0.17).
received donor hepatitis C-positive kidneys was better or worse than the survival of such patients had they remained on dialysis. The possibility remains, however, that this patient group could be deemed a somewhat more urgent transplant priority because of access failure, poor dialysis tolerance, or other problems indeterminable in the database.
Certain limitations of the current analysis must be considered. Because the study was retrospective, the reason behind the decision to offer a hepatitis C-positive kidney to a given transplant candidate could not be determined. Furthermore, not all donor kidneys positive for hepatitis C antibody are infective. This is relevant because Pereira et al. (38) and Natov et al. (39) also reported that only donors with HCV antigen in the peripheral blood circulation are likely to transmit HCV to the kidney. Fortunately, hepatitis C infection before seroconversion in potential donors (specifically, blood donors) is rare (40) . The specific HCV used to establish hepatitis C status was unknown, as were HCV genotypes, although ELISA testing (41) is almost universally performed for donor cadaver kidneys due to time constraints. However, Natov et al. (42) reported that HCV RNA was detected in 81% of patients positive by ELISA-3, which was available in 1993 (43) but may not have been in wide use until a few years later. The present study showed the percentage of HCV-positive donors was constant over the time of the study, arguing against a significant increase in sensitivity of HCV serology in the study population. Liver biopsy results, which may have been useful in riskstratifying patients for posttransplant liver disease, were unavailable as well. De novo GN, an important cause of graft loss in transplant recipients with HCV, was not listed as a cause of graft loss in the USRDS. There was incomplete information on comorbidities, although transplant patients are consistently screened for serious diseases before placement on the cadaveric waiting list. Longenecker et al. (44) , found that the specificity of CMS Form 2728 was Ͼ90% for cardiovascular disease. Similarly, causes of death were incomplete in nearly 50% of patients, precluding firm conclusions on this matter. Nonetheless, the analysis includes nearly the entire transplant population and thus minimizes the likelihood of sampling error and referral bias.
Because of study limitations, firm recommendations regarding the use of donor hepatitis C-positive kidneys should not be proffered. Specifically, we cannot yet recommend avoiding donor hepatitis C-positive kidneys in all circumstances. However, this study does appear to refute the assumption that donor hepatitis C-positive kidneys may be entirely safe for hepatitis C-positive recipients and the elderly. Until the link between donor hepatitis C-positive kidneys and patient mortality is better established, patient counseling practices may need to be altered, especially for hepatitis C-positive recipients who are offered donor hepatitis C-positive kidneys.
